Related Experiment Video

Updated: Apr 12, 2026

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

28.8K

Targeted drug delivery systems for pancreatic cancer

Vaibhav Khare, Noor Alam, Ankit Saneja

    Journal of Biomedical Nanotechnology
    |May 23, 2015
    PubMed

    Insights

    Effective pancreatic cancer treatment requires targeted drug delivery. Novel nanomedicines and therapeutic agents show promise in overcoming challenges like the tumor microenvironment for better patient outcomes.

    Area of Science:

    • Oncology
    • Nanomedicine
    • Drug Delivery Systems

    Background:

    • Pancreatic cancer is often diagnosed late and shows poor response to chemotherapy, leading to high mortality rates.
    • Effective treatment necessitates selective drug delivery to cancer cells while minimizing side effects.
    • Challenges in pancreatic cancer drug targeting include the dense stroma, poor vascularity, and high interstitial fluid pressure.

    Purpose of the Study:

    • To review factors hindering pancreatic cancer drug targeting efficacy.
    • To explore cellular targets for site-specific drug delivery in pancreatic cancer.
    • To highlight the application of novel drug delivery systems and nanomedicines in pancreatic cancer therapy.

    Main Methods:

    • Literature review of current research on pancreatic cancer drug targeting.
    • Analysis of challenges posed by the tumor microenvironment.
    • Examination of novel drug delivery systems and their potential applications.

    Main Results:

    • Identified key barriers to effective drug delivery in pancreatic cancer.
    • Discussed various cellular targets for precise therapeutic intervention.
    • Detailed the burgeoning use of nanoparticles, liposomes, quantum dots, micelles, and drug conjugates.
    • Highlighted the clinical trial potential of target-based agents and nanomedicines.

    Conclusions:

    • Overcoming the pancreatic cancer tumor microenvironment is crucial for therapeutic success.
    • Novel drug delivery systems offer promising strategies for targeted treatment.
    • Nanomedicines and targeted agents are advancing pancreatic cancer therapy, with ongoing clinical evaluations.

    More Related Videos

    Pancreatic Duct Infusion: An Effective and Selective Method of Drug and Viral Delivery06:03

    Pancreatic Duct Infusion: An Effective and Selective Method of Drug and Viral Delivery

    Published on: September 30, 2021

    5.7K
    Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier10:16

    Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

    Published on: February 8, 2017

    8.1K

    Related Concept Videos

    Modified-Release Drug Delivery Systems: Site-Targeted01:24

    Modified-Release Drug Delivery Systems: Site-Targeted

    Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
    130
    Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

    Site-Targeted Drug Delivery Systems: Polymeric Carriers

    Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
    125
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    9.2K
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    1.8K
    Modified-Release Drug Delivery Systems: Classification01:23

    Modified-Release Drug Delivery Systems: Classification

    Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
    287
    Drug Delivery Systems: Different Types01:27

    Drug Delivery Systems: Different Types

    Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
    317